☆ 4.6 Article

Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis

Alyssa A. Toorop et al.

Summary: The study evaluated the change in natalizumab trough drug levels when switching from intravenous to subcutaneous administration. It was found that the drug levels were on average 55% lower with subcutaneous administration, leading to very low levels in some patients. Monitoring of trough drug levels is advised when switching to subcutaneous administration in patients with low intravenous drug levels, higher body mass index, or extended treatment intervals.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Add to Collection

Article Clinical Neurology

Serum neurofilament light levels in natalizumab-treated patients with multiple sclerosis who switch to extended interval dosing from every-4-week dosing in real-world clinical practice

John Foley et al.

Summary: This study aimed to compare levels of sNfL in patients with MS who switched from natalizumab every 4 weeks (Q4W) to extended interval dosing (EID) and patients who remained on Q4W dosing. The results showed no significant difference in sNfL levels between patients who switched to EID and those who stayed on Q4W dosing, suggesting that the effectiveness of natalizumab is maintained in patients who switch to EID.

MULTIPLE SCLEROSIS JOURNAL (2023)

Add to Collection

Review Clinical Neurology

Extended dosing of monoclonal antibodies in multiple sclerosis

Zoe L. E. van Kempen et al.

Summary: Over the past two decades, there has been a significant increase in treatment options for patients with multiple sclerosis (MS). Personalized or extended interval dosing, particularly using monoclonal antibodies, is being increasingly explored as a way to optimize MS therapy. Studies on altered dosing intervals of monoclonal antibodies in MS treatment are ongoing and provide promising insights for future research and clinical practice.

MULTIPLE SCLEROSIS JOURNAL (2022)

Add to Collection

Article Clinical Neurology

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

John F. Foley et al.

Summary: This study aimed to assess the safety and efficacy of natalizumab dosing once every 6 weeks compared to once every 4 weeks in patients with relapsing-remitting multiple sclerosis. The results showed a numerical difference in the number of new or newly enlarging T2 hyperintense lesions at week 72 between the two dosing regimens, which reached statistical significance under the secondary estimand. The safety profiles of natalizumab dosing once every 6 weeks and once every 4 weeks were similar.

LANCET NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis

Marcello Moccia et al.

NEURODEGENERATIVE DISEASE MANAGEMENT (2022)

Add to Collection

Article Clinical Neurology

No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab

Magnus Johnsson et al.

Summary: This study investigated the effect of extending the dosing interval of natalizumab (NZ) from 4 to 6 weeks on serum neurofilament light chain (sNfL) concentrations in patients with relapsing-remitting multiple sclerosis (RRMS). The results showed that extending the NZ dosing interval did not increase axonal damage in patients with RRMS, as determined with sNfL.

MULTIPLE SCLEROSIS JOURNAL (2022)

Add to Collection

Article Clinical Neurology

Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab

Alyssa A. Toorop et al.

Summary: Two patients with relapsing-remitting MS developed carryover PML after switching from natalizumab to ocrelizumab. Despite mild immune reconstitution inflammatory syndrome (IRIS) and increasing NfL levels, PML-IRIS lesions stabilized after treatment and both patients continued therapy with ocrelizumab.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)

Add to Collection

Article Clinical Neurology

MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study

Stefania Federica De Mercanti et al.

Summary: Extending the dosing interval of natalizumab (EID) does not increase the risk of active lesions on MRI compared to standard interval dosing (SID) in JCV-positive multiple sclerosis patients.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2021)

Add to Collection

Article Clinical Neurology

A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis

Maria Trojano et al.

Summary: The study aimed to examine the efficacy, safety, and tolerability of natalizumab administered via various regimens in RRMS patients. The results showed that natalizumab 300 mg subcutaneous Q4W was comparable to 300 mg intravenous Q4W dosing with respect to efficacy, pharmacokinetics/pharmacodynamics, and safety.

MULTIPLE SCLEROSIS JOURNAL (2021)

Add to Collection

Article Immunology

Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study

Javier Riancho et al.

Summary: Observational study on the long-term effectiveness of natalizumab with extended interval dosing (EID) in multiple sclerosis patients treated for over 7 years showed that EID preserved treatment efficacy and prevented disability worsening during follow-up. Patients treated with natalizumab for the first time showed slightly better response to EID therapy compared to those previously treated with other immunosuppressive drugs.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Clinical Neurology

No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)

Helmut Butzkueven et al.

Summary: This study, using propensity score-matched cohorts from the Tysabri Observational Program, demonstrates that the effectiveness of natalizumab is maintained in patients who switch from every-4-week (Q4W) dosing to every-6-week (Q6W) dosing after more than 1 year of treatment. Annualized relapse rates, probability of remaining relapse free, and safety outcomes did not differ significantly between Q6W and Q4W patients.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2021)

Add to Collection

Article Clinical Neurology

Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?

Marinella Clerico et al.

NEUROTHERAPEUTICS (2020)

Add to Collection

Article Clinical Neurology

Pharmacodynamics of natalizumab extended interval dosing in MS

Lana Zhovtis Ryerson et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)

Add to Collection

Article Clinical Neurology

Personalized extended interval dosing of natalizumab in MS A prospective multicenter trial

Zoe L. E. van Kempen et al.

NEUROLOGY (2020)

Add to Collection

Article Clinical Neurology

Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis

Clara Grazia Chisari et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)

Add to Collection

Article Clinical Neurology

Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing

John F. Foley et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)

Add to Collection

Article Clinical Neurology

Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab

I Dekker et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)

Add to Collection

Article Clinical Neurology

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing

Lana Zhovtis Ryerson et al.

NEUROLOGY (2019)

Add to Collection

Article Clinical Neurology

The natalizumab wearing-off effect End of natalizumab cycle, recurrence of MS symptoms

Zoe L. E. van Kempen et al.

NEUROLOGY (2019)

Add to Collection

Article Clinical Neurology

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing

Zoe L. E. van Kempen et al.

MULTIPLE SCLEROSIS JOURNAL (2018)

Add to Collection

Review Clinical Neurology

Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters

Nicholas Schwab et al.

MULTIPLE SCLEROSIS JOURNAL (2018)

Add to Collection

Article Clinical Neurology

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing

Zoe L. E. van Kempen et al.

MULTIPLE SCLEROSIS JOURNAL (2018)

Add to Collection

Review Clinical Neurology

Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters

Nicholas Schwab et al.

MULTIPLE SCLEROSIS JOURNAL (2018)

Add to Collection

Review Clinical Neurology

Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis

Bernard M. J. Uitdehaag

CNS DRUGS (2018)

Add to Collection

Review Gastroenterology & Hepatology

Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease

Christopher A. Lamb et al.

JOURNAL OF CROHNS & COLITIS (2018)

Add to Collection

Article Clinical Neurology

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

Alan J. Thompson et al.

LANCET NEUROLOGY (2018)

Add to Collection

Article Clinical Neurology

Efficacy and safety of natalizumab extended interval dosing

Bassem Yamout et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2018)

Add to Collection

Review Clinical Neurology

Neurofilaments as biomarkers in neurological disorders

Michael Khalil et al.

NATURE REVIEWS NEUROLOGY (2018)

Add to Collection

Article Pharmacology & Pharmacy

Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis

Kumar Kandadi Muralidharan et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2017)

Add to Collection

Article Clinical Neurology

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients

Tatiana Plavina et al.

NEUROLOGY (2017)

Add to Collection

Article Clinical Neurology

α4-integrin receptor desaturation and disease activity return after natalizumab cessation

Tobias Derfuss et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)

Add to Collection

Article Clinical Neurology

Extended interval dosing of natalizumab in multiple sclerosis

L. Zhovtis Ryerson et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2016)

Add to Collection

Review Clinical Neurology

EVIDENCE-BASED GUIDELINES MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-establishing disease prognosis and monitoring patients

Mike P. Wattjes et al.

NATURE REVIEWS NEUROLOGY (2015)

Add to Collection

Article Clinical Neurology

Extended interval dosing of natalizumab: a two-center, 7-year experience

Roberto Bomprezzi et al.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2014)

Add to Collection

Article Clinical Neurology

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis

Anke Vennegoor et al.

MULTIPLE SCLEROSIS JOURNAL (2013)

Add to Collection

Article Biochemical Research Methods

Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody

Theo Rispens et al.

ANALYTICAL BIOCHEMISTRY (2011)

Add to Collection

Article Clinical Neurology

Natalizumab Drug Holiday in Multiple Sclerosis: Poorly Tolerated

Joep Killestein et al.

ANNALS OF NEUROLOGY (2010)

Add to Collection

Article Clinical Neurology

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

B. O. Khatri et al.

NEUROLOGY (2009)

Add to Collection

Article Medicine, General & Internal

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

CH Polman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.